Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of panic disorder comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key peripheral arterial disease patient populations, covering 171…
Clarivate Epidemiology’s coverage of restless legs syndrome (RLS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Epi Data Slicer
Clarivate Epidemiology’s coverage of obstructive sleep apnea (OSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of monoclonal gammopathy of undetermined significance (MGUS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical…
Clarivate Epidemiology’s coverage of endometrial carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of endometrial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations, covering 171 countries and…
Clarivate Epidemiology’s coverage of myasthenia gravis (MG) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MG for each…
Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…
The number of diagnosed prevalent cases of JIA in the countries under study will remain relatively stable over the 20 years of our forecast period. Of the countries considered in this analysis…